Comparative efficacy of five long‐term weight loss drugs: quantitative information for medication guidelines
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: Quantitative information is scarce in current obesity medication guidelines, and they do not clearly reflect the differences in the efficacy characteristics among various drugs. This study quantitatively assessed the efficacy characteristics of five FDA‐approved long‐term weight loss drugs. Potentially eligible studies were obtained from public databases. Using the differences in the weight change from baseline between the drug group and the corresponding placebo group as the major indicator of efficacy, a time‐effect model was established, and crucial pharmacodynamic parameters, such as the maximal efficacy, drug onset time and rate of body weight regain after the maximal efficacy point, were used to reflect the differences in efficacy among the five drugs. Finally, 50 reports (involving 43,443 participants) were included. After deducting the placebo effects, the maximal efficacies (95% CI) of orlistat (120 mg), lorcaserin, naltrexone–bupropion, phentermine–topiramate (PT, 7.5/46 mg) and liraglutide were −2.94 (−5.82, −1.27), −3.06 (−4.39, −1.71), −6.15 (−9.78, −3.25), −7.45 (−9.76, −3.88) and −5.50 (−10.62, −2.97) kg at weeks 60, 54, 67, 59 and 65 respectively, and their rates of body weight regain were 0.51, 0.48, 0.91, 1.27and 0.43 kg per year respectively. The 1‐year dropout rates of orlistat, lorcaserin, naltrexone‐bupropion, PT and liraglutide were 29.0, 40.9, 49.1, 34.9 and 24.3% respectively. In addition, a significant dose–effect correlation was observed for orlistat and PT. This study provides valid quantitative information for medication guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“Studies have suggested that long-term diet and weight loss could influence the secretion of appetite-related circulating mediators in the body and that the changes in these circulating mediators were maintained after 1 year (22).”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“After the literature search deadline of this study, one clinical study reported the 160-week therapeutic efficacy of liraglutide (28).”
MethodPersistent microbiome alterations modulate the rate of post-dieting weight regain
Thaiss, C. A., Itav, S., Rothschild, D., Meijer, M. T., Levy, M., Moresi, C., Dohnalová, L., Braverman, S., Rozin, S., Malitsky, S., et al. (2016) · Nature · doi:10.1038/nature20796 · Cited by 471 · cited 1×
“Moreover, the most recent study showed that the body weight regain due to long-term diet may be associated with a change in enteric organisms (23).”
BackgroundGuidelines (2013) for managing overweight and obesity in adults
(2014) · Obesity · doi:10.1002/oby.20818 · Cited by 172
Food and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Cited by
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
“Data are from Dong et al., 2017 (334).”
MethodEfficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis
Hedjoudje, A., Abu Dayyeh, B. K., Cheskin, L. J., Adam, A., Neto, M. G., Badurdeen, D., Morales, J. G., Sartoretto, A., Nava, G. L., Vargas, E., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.022 · Cited by 266
Obesity and cardiovascular health
Welsh, A., Hammad, M., Piña, I. L., & Kulinski, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae025 · Cited by 239
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Bray, G. A., & Ryan, D. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14200 · Cited by 148
Differential mechanisms affecting weight loss and weight loss maintenance
Rosenbaum, M., & Foster, G. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00864-1 · Cited by 61
Legend of Weight Loss: A Crosstalk Between the Bariatric Surgery and the Brain
Lin, Z., & Qu, S. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04474-8 · Cited by 28
Metadata
- Authors
- Dong, Z., Xu, L., Liu, H., Lv, Y., Zheng, Q., & Li, L.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2017-10-10
- Volume
- 18
- Issue
- 12
- Pages
- 1377-1385
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2764147799
- Cited by
- 57
- References
- 9
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.